Detalhe da pesquisa
1.
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Blood
; 128(21): 2510-2516, 2016 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27697771
2.
Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
Blood
; 127(9): 1128-37, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26675347
3.
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Blood
; 123(6): 837-42, 2014 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-24264230
4.
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex.
J Natl Compr Canc Netw
; 14(10): 1274-1281, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27697981
5.
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Lancet Oncol
; 16(6): 704-15, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25925619
6.
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project.
Cancer
; 121(7): 1032-9, 2015 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25492236
7.
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Br J Haematol
; 171(5): 763-75, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26471982
8.
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Br J Haematol
; 169(4): 506-19, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25712263
9.
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.
Blood
; 122(4): 499-506, 2013 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23692856
10.
Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Ann Hematol
; 94(12): 2025-32, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26411584
11.
Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.
Ann Hematol
; 94(4): 633-41, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25630297
12.
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
J Natl Compr Canc Netw
; 13(3): 326-62, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25736010
13.
Circulating CD4(+)CXCR5(+) T Cells Exacerbate B Cell Antibody Production in Crohn's Disease Through IL-21 Secretion.
Immunol Invest
; 44(7): 665-77, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26436852
14.
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.
Cancer
; 120(13): 1993-9, 2014 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24706502
15.
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.
Blood
; 119(9): 2093-9, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22234679
16.
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
Blood
; 119(16): 3698-704, 2012 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22389254
17.
Non-Hodgkin's lymphomas, version 4.2014.
J Natl Compr Canc Netw
; 12(9): 1282-303, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25190696
18.
Non-Hodgkin's lymphomas, version 2.2014.
J Natl Compr Canc Netw
; 12(6): 916-46, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24925202
19.
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Cancer
; 119(20): 3662-71, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23921646
20.
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Br J Haematol
; 162(5): 657-69, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23826755